



North Carolina
State Health Plan
FOR TEACHERS AND STATE EMPLOYEES



Pharmacy & Therapeutics Committee November 2014 Meeting Summary

Board of Trustees Meeting

January 22, 2015

A Division of the Department of State Treasurer

Updates to Utilization Management Programs

Programs	Update
Compound Medications Prior Authorization	Implemented ESI's compound program which looks at all the compound ingredients instead of only the primary ingredient.
Kuvan Prior Authorization	Policy updated to include all Kuvan products.
Ilaris Prior Authorization	Policy updated to include Systemic Juvenile Idiopathic Arthritis (SJIA) criteria requirements.
Promacta Prior Authorization	Policy updated to allow coverage for new indication in patients with severe aplastic anemia.
Tetracycline Step Therapy	Policy updated to add new product Acticlate as a non-preferred step 2 medication.
Zelboraf Prior Authorization	Policy updates consistent with recent National Comprehensive Cancer Network (NCCN) clinical guidelines.
Buprenorphine and Buprenorphine/Naloxone Prior Authorization and Quantity Limits	Policy updated to add new medication Bunavail.

Updates to Utilization Management Programs

Programs	Update
Omega-3 Fatty Acid Products Prior Authorization	Policy updated to add new medications Epanova and Omtryg.
Weight Loss Agents Prior Authorization	Policy updated to add new medication Contrave.
Immune Globulin Prior Authorization	Policy updated to add new subcutaneous medication HyQvia.
Otezla Prior Authorization	Policy updated to add plaque psoriasis as an approved indication.
Hereditary Angioedema Prior Authorization	Policy updated to add criteria for Cinryze and Berinert and new medication Ruconest.
Humira Prior Authorization	Policy updated to add coverage for pediatric Crohn's patients 6 years of age and older.
Stelara Prior Authorization and Step Therapy	Policy updated to remove the step therapy requirements for Stelara.

Updates to Utilization Management Programs

Programs	Update
Hepatitis C Agents Prior Authorization	Policy updates consistent with guidance from American Association for the Study of Liver Diseases.
Multiple Sclerosis Prior Authorization	Policy added for Plegridy which was recently FDA approved for the treatment of relapsing forms of multiple sclerosis.
Migraine Agents Preferred Step Therapy and Quantity Limit Policy	Policy updated to add new 4 mg strength of Sumavel DosePro injection.
Anti-emetic Prior Authorization and Quantity Limit Policy	Emend policy updated to add new antiemetic Akynzeo.
Androgen and Anabolic Steroid Prior Authorization and Step Therapy Policy	Policy updated to add new medications, Vogexlo and testosterone gel, and change the coverage duration for all indications from 5 years to 12 months with the exception of the treatment of delayed puberty where coverage duration is 6 months.
Growth Hormones Step Therapy Policy	Humatrope is now non-preferred step 2; Norditropin and Genotropin are the preferred step 1 medications.

Updates to Utilization Management Programs

Programs	Update
Oral Corticosteroid Inhalers Preferred Step Therapy Program	Policy updated to add new medication Aerospan and new formulation of Asmanex HFA.
Osteoporosis Step Therapy Policy	Policy updated to add generic risedronate (Actonel) 150 mg tablets as a preferred step 1 agent.
Topical Acne Policies	Policies updated to reflect all available strengths for applicable products.
Angiotensin Receptor Blocker Step Therapy Policy	Policy updated to add generic valsartan as a preferred step 1 medication and brand Diovan as step 2.
Antifungal Prior Authorization Policy	Policy updated to add new medications Jublia and Kerydin.
Pulmonary Arterial Hypertension Prior Authorization Policies	Policy updates consistent with treatment guidelines.
Nasal Steroids Step Therapy	Policy updated to add generic budesonide as a preferred step 1 medication and add brand QNASL as a non-preferred step 2 medication.

New Utilization Management Programs Reviewed

Program	Description	Member Impact	Estimated Projected Savings	P&T Recommendation	Target Implementation
Overactive bladder Step Therapy Program	Step Therapy	728	\$925,000	Yes	TBD
Pulmonary Fibrosis Medication	Prior Authorization	Current users grand-fathered	Not modeled (new products)	Yes	1/1/2015
Sublingual Immuno-allergens	Prior Authorization	Current users grand-fathered	Not modeled (new products)	Yes	2/16/15

New Drugs for Formulary Consideration

Drug	Indication	Tier Placement
Duavee (bazedoxifene/conjugated estrogens tablets)	Menopausal vasomotor symptoms and prevention of postmenopausal osteoporosis	3
Zohydro ER (extended-release hydrocodone capsules)	Pain management	3
Xartemis XR (oxycodone/APAP extended-release tablets)	Pain management	3
Anoro Ellipta (umeclidinium/vilanterol inhalation powder)	COPD	2
Grastek (timothy grass pollen extract)	Allergen immunotherapy	3
Ragwitek (short ragweed pollen extract)	Allergen immunotherapy	3

New Drugs for Formulary Consideration

Drug	Indication	Tier Placement
Farxiga (dapagliflozin tablets)	Type 2 Diabetes Mellitus	3
Jardiance (empagliflozin tablets)	Type 2 Diabetes Mellitus	3
Invokana (canagliflozin) (previously reviewed)	Type 2 Diabetes Mellitus	2
Aptiom (eslicarbazepine tablets)	Seizures	3
Luzu (luliconazole 1% topical cream)	Topical antifungal	3
Zontivity (vorapaxar tablets)	Anti-platelet	3
Otrexup (methotrexate injection)	Rheumatoid arthritis; polyarticular juvenile idiopathic arthritis; severe psoriasis	3
Hemangeol (propranolol oral solution)	Infantile hemangioma	3

Additional Topics Discussed

- The Affordable Care Act (ACA) Preventive Medication List will be updated for the calendar year 2015 with the following additions:
 - Coverage of medications for primary prevention of breast cancer at a \$0 cost-share for women who are at high risk and enrolled in the Enhanced 80/20 Plan or Consumer Directed Health Plan (CDHP) if authorization criteria are met.
 - Tobacco cessation category added coverage of OTC lozenges through the QuitlineNC, prescription brand Chantix limited to a six month supply in 12 months and for generic extended-release bupropion 12 hour.
- Oral Long-Acting Opioid Quantity Limit policy was implemented on November 3, 2014, as a quantity limit policy and did not incorporate a step therapy policy as initially proposed.
- A UV Light Therapy Pilot Program has been proposed by BCBSNC for the treatment of moderate-to-severe psoriasis. This program will work with 24 BCBSNC contracted dermatologists in North Carolina.